<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00292370</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-006-04F</org_study_id>
    <nct_id>NCT00292370</nct_id>
  </id_info>
  <brief_title>Quetiapine Augmentation for Treatment-resistant PTSD</brief_title>
  <official_title>A Placebo-controlled Trial of Adjunctive Quetiapine for Refractory PTSD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the response of veterans with PTSD without an optimal
      response to paroxetine to quetiapine augmentation versus placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a two-site study designed to evaluate the efficacy and safety of quetiapine
      augmentation of paroxetine treatment in veterans with PTSD who have failed to respond to
      paroxetine treatment.

      In Phase I, eligible patients will take open-label paroxetine (up to 60 mg daily) for 8
      weeks. Patients who are refractory (less than 30% reduction in CAPS scores or a minimum CAPS
      score of 50 at week 8) and have PTSD symptoms of at least moderate severity on CGI-S will be
      eligible for the second phase. In Phase II, patients will continue taking open-label
      paroxetine and will be randomized to the addition of quetiapine (up to 800 mg daily) or
      placebo for 8 weeks in a double-blind fashion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Clinician-Administered PTSD Scale for DSM-IV Total Score.</measure>
    <time_frame>From baseline (week 8) to endpoint (week 16 or termination)</time_frame>
    <description>The Clinician-Administered PTSD Scale for DSM-IV (CAPS) is described in the National Center for PTSD Instruction Manual (November 2000) as a semi-structured clinical interview designed to assess the seventeen symptoms for Post Traumatic Stress Disorder (PTSD) outlined in the DSM-IV, along with five associated features. Ratings are made on a 5 point continuum from the lowest frequency or intensity to the highest. Total CAPS score is a summed score that ranges from 0 to 136 where 0 is asymptomatic and higher scores equal more severe PTSD symptomatology. Also, a change in total CAPS score of 15 points was proposed as clinically significant change.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PANSS,HAMD,CGI,DTS, PSQI,PSQI-A, Dream/Sleep Diary,Q-LES-Q,SDS,ASEX,AIMS, BAS, SAS</measure>
    <time_frame>Baseline to endpoint change scores</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Combat Disorders</condition>
  <condition>Stress Disorders, Post-Traumatic</condition>
  <arm_group>
    <arm_group_label>Arm 1: Open Label (OL) Paroxetine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Open-label Paroxetine In Phase I, eligible participants will take open-label (OL) Paroxetine (up to 60 mg) daily for 8 weeks. Participants who are refractory (less than 30% reduction in CAPS scores or a minimum CAPS of 50 at week 8) and have PTSD symptoms of at least moderate severity on CGI-S will be eligible for Phase II.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 OL Paroxetine + DB Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In Phase II, participants will continue taking open label paroxetine and will be randomized to the addition of placebo for 8 weeks in a double-blind (DB) fashion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: OL Paroxetine + DB Quetiapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Phase II, participants will continue taking open label paroxetine and will be randomized to the addition of quetiapine (up to 800 mg daily) for 8 weeks in a double blind fashion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Open Label (OL) Paroxetine</intervention_name>
    <description>Open-label Paroxetine</description>
    <arm_group_label>Arm 1: Open Label (OL) Paroxetine</arm_group_label>
    <arm_group_label>Arm 2 OL Paroxetine + DB Placebo</arm_group_label>
    <arm_group_label>Arm 3: OL Paroxetine + DB Quetiapine</arm_group_label>
    <other_name>Paxil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Double-blind placebo taken with OL paroxetine</description>
    <arm_group_label>Arm 2 OL Paroxetine + DB Placebo</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine</intervention_name>
    <description>Double-blind quetiapine taken with OL paroxetine</description>
    <arm_group_label>Arm 3: OL Paroxetine + DB Quetiapine</arm_group_label>
    <other_name>Seroquel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Veteran age 18 to 75.

          -  Competent to give informed consent.

          -  Meeting DSM-IV criteria for PTSD.

          -  Minimal CAPS score of 50 at baseline.

          -  If female of childbearing potential, patient must have a negative pregnancy test and,
             if sexually active, be using a medically approved contraceptive method.

          -  Patients who have not taken psychiatric medications within 1 week prior to study entry
             (except fluoxetine [5 weeks])

               -  monoamine oxidase inhibitors (MAOIs [4 weeks])

               -  depot neuroleptics [4 weeks])

               -  or any investigational drug within 30 days prior to study enrollment.

          -  To be eligible for Phase II

               -  patients must be refractory to paroxetine in Phase I, as defined by less than 30%
                  reduction in CAPS scores or a minimum CAPS score of 50 at week 8

               -  must have PTSD symptoms at least moderate severity on CGI-S

               -  and must have been compliant with study medicine in Phase I, as defined by taking
                  at least 80% of prescribed doses.

        Exclusion Criteria:

          -  History of sensitivity to paroxetine or quetiapine.

          -  Failure to respond to a prior adequate therapeutic trial i.e. minimum of 8 weeks at
             maximum tolerated dose of paroxetine (up to 60 mg daily) or quetiapine (up to 800 mg
             daily).

          -  Women who are

               -  breast-feeding

               -  pregnant

               -  expect to become pregnant during the course of the study

               -  or are sexually active and are not using a medically acceptable method of birth
                  control.

          -  Presence of clinically significant hepatic

               -  cardiovascular

               -  or other medical conditions that may prevent safe administration of paroxetine or
                  quetiapine

               -  or any other clinically significant unstable medical conditions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark B Hamner, MD BS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ralph H. Johnson VA Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Birmingham VA Medical Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tuscaloosa VAMC</name>
      <address>
        <city>Tuscaloosa</city>
        <state>Alabama</state>
        <zip>35404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ralph H. Johnson</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401-5799</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Weathers FW, Keane TM, Davidson JR. Clinician-administered PTSD scale: a review of the first ten years of research. Depress Anxiety. 2001;13(3):132-56. Review.</citation>
    <PMID>11387733</PMID>
  </reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2006</study_first_submitted>
  <study_first_submitted_qc>February 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2006</study_first_posted>
  <results_first_submitted>February 14, 2014</results_first_submitted>
  <results_first_submitted_qc>June 27, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 1, 2014</results_first_posted>
  <last_update_submitted>June 27, 2014</last_update_submitted>
  <last_update_submitted_qc>June 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atypical Antipsychotics</keyword>
  <keyword>Controlled Trial</keyword>
  <keyword>Paroxetine</keyword>
  <keyword>Quetiapine</keyword>
  <keyword>Stress Disorders, Post-Traumatic</keyword>
  <keyword>Treatment refractory</keyword>
  <keyword>Treatment resistant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
    <mesh_term>Combat Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
    <mesh_term>Paroxetine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1/Open-Label (OL) Paroxetine</title>
          <description>Phase I : Open-label Paroxetine
In Phase I, eligible participants will take open-label (OL) paroxetine (up to 60 mg daily) for 8 weeks. Participants who are refractory (less than 30% reduction in CAPS scores or a minimum CAPS score of 50 at week 8) and have PTSD symptoms of at least moderate severity on CGI-S will be eligible for Phase II</description>
        </group>
        <group group_id="P2">
          <title>Arm 2/OL Paroxetine &amp; Double-blind Placebo</title>
          <description>Phase II : Double-blind placebo
In Phase II, participants will continue taking open-label paroxetine and will be randomized to the addition of placebo for 8 weeks in a double-blind fashion.</description>
        </group>
        <group group_id="P3">
          <title>Arm 3/OL Paroxetine &amp; Double-blind Quetiapine</title>
          <description>Phase II : Double-blind quetiapine
In Phase II, participants will continue taking open-label paroxetine and will be randomized to the addition of quetiapine for 8 weeks in a double-blind fashion.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase I - Open-Label Paroxetine (OLP)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase II: OLP + DB Quetiapine or Placebo</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">78 Completed Ph I
28 Excluded Ph II:
20 responded
7 declined
1 medical
50 to Arm 2 &amp; 3</participants>
                <participants group_id="P2" count="25">25 out of 50 in Arm I PhI, eligible for Ph II</participants>
                <participants group_id="P3" count="25">25 out of 50 in Arm I PhI, eligible for Ph II</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Period 1 or Phase I, 124 patients enrolled in Arm 1/Open-Label Paroxetene for 8 weeks.
Period 2 or Phase II (intervention period), 50 patients enrolled from week 8 to week 16; 25 in Arm 2/OL paroxetene &amp; DB Placebo, 25 in Arm 3/OL paroxetene &amp; DB quetiapine.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm 1/Open-Label (OL) Paroxetine</title>
          <description>Phase I : Open-label Paroxetine
In Phase I, eligible participants will take open-label (OL) paroxetine (up to 60 mg daily) for 8 weeks. Participants who are refractory (less than 30% reduction in CAPS scores or a minimum CAPS score of 50 at week 8) and have PTSD symptoms of at least moderate severity on CGI-S will be eligible for Phase II</description>
        </group>
        <group group_id="B2">
          <title>Arm 2/OL Paroxetine &amp; Double-blind Placebo</title>
          <description>Phase II: Double-blind placebo
In Phase II, participants will continue taking open-label paroxetine and will be randomized to the addition of placebo for 8 weeks in a double-blind fashion.</description>
        </group>
        <group group_id="B3">
          <title>Arm 3/OL Paroxetine &amp; Double-blind Quetiapine</title>
          <description>Phase II: Double-blind quetiapine
In Phase II, participants will continue taking open-label paroxetine and will be randomized to the addition of quetiapine in a double-blind fashion.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="124"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="174"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age - OL Paroxetine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.32" spread="13.23"/>
                    <measurement group_id="B2" value="NA">DB participants not randomized in OL phase I (period 1)</measurement>
                    <measurement group_id="B3" value="NA">DB participants not randomized in OL phase I (period 1)</measurement>
                    <measurement group_id="B4" value="52.32" spread="13.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age - Double Blind</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Only randomized participants counted in phase II (period 2).</measurement>
                    <measurement group_id="B2" value="57.17" spread="8.74"/>
                    <measurement group_id="B3" value="54.45" spread="13.69"/>
                    <measurement group_id="B4" value="54.76" spread="11.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <description>Gender for Open - Label (OL) population.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Gender OL Females</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="NA">Double-Blind participants not randomized in OL Phase</measurement>
                    <measurement group_id="B3" value="NA">Double-Blind participants not randomized in OL Phase</measurement>
                    <measurement group_id="B4" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gender OL Males</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="NA">Double-Blind participants not randomized in OL Phase</measurement>
                    <measurement group_id="B3" value="NA">Double-Blind participants not randomized in OL Phase</measurement>
                    <measurement group_id="B4" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <description>Gender for Double-Blind phase II</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Females Double Blind</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Only randomized participants counted in Phase II (period 2)</measurement>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Males Double Blind</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Only randomized participants counted in Phase II (period 2)</measurement>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Race/Ethnicity for Open-Label Phase participants</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>OL Amer Indian/ Alask Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="NA">DB participants not randomized in OL phase I</measurement>
                    <measurement group_id="B3" value="NA">DB participants not randomized in OL phase I</measurement>
                    <measurement group_id="B4" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OL African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="NA">DB participants not randomized in OL phase I</measurement>
                    <measurement group_id="B3" value="NA">DB participants not randomized in OL phase I</measurement>
                    <measurement group_id="B4" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OL White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="NA">DB participants not randomized in OL phase I</measurement>
                    <measurement group_id="B3" value="NA">DB participants not randomized in OL phase I</measurement>
                    <measurement group_id="B4" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OL Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="NA">DB participants not randomized in OL phase I</measurement>
                    <measurement group_id="B3" value="NA">DB participants not randomized in OL phase I</measurement>
                    <measurement group_id="B4" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Race/Ethnicity for Double-Blind participants</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>DB Amer Indian/ Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Only randomized participants counted in Phase II (period 2)</measurement>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Only randomized participants counted in Phase II (period 2)</measurement>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Only randomized participants counted in Phase II (period 2)</measurement>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Unknown/ Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Only randomized participants counted in Phase II (period 2)</measurement>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="NA">Same region as in OL phase</measurement>
                    <measurement group_id="B3" value="NA">Same region as in OL phase</measurement>
                    <measurement group_id="B4" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Years of Education</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Education - Open Label (OL) Population</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.12" spread="2.05"/>
                    <measurement group_id="B2" value="NA">DB participants not yet randomized in OL, phase I.</measurement>
                    <measurement group_id="B3" value="NA">DB participants not yet randomized in OL, phase I.</measurement>
                    <measurement group_id="B4" value="13.12" spread="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Education - Double Blind (DB), Phase II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Only randomized participants counted in DB, phase II.</measurement>
                    <measurement group_id="B2" value="13.22" spread="2.74"/>
                    <measurement group_id="B3" value="12.55" spread="1.53"/>
                    <measurement group_id="B4" value="12.89" spread="2.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Clinician-Administered PTSD Scale for DSM-IV Total Score.</title>
        <description>The Clinician-Administered PTSD Scale for DSM-IV (CAPS) is described in the National Center for PTSD Instruction Manual (November 2000) as a semi-structured clinical interview designed to assess the seventeen symptoms for Post Traumatic Stress Disorder (PTSD) outlined in the DSM-IV, along with five associated features. Ratings are made on a 5 point continuum from the lowest frequency or intensity to the highest. Total CAPS score is a summed score that ranges from 0 to 136 where 0 is asymptomatic and higher scores equal more severe PTSD symptomatology. Also, a change in total CAPS score of 15 points was proposed as clinically significant change.</description>
        <time_frame>From baseline (week 8) to endpoint (week 16 or termination)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 2 OL Paroxetine + DB Placebo</title>
            <description>In Phase II, participants will continue taking open label paroxetine and will be randomized to the addition of placebo for 8 weeks in a double-blind (DB) fashion.
Open Label (OL) Paroxetine: Open-label Paroxetine
Placebo: Double-blind placebo taken with OL paroxetine</description>
          </group>
          <group group_id="O2">
            <title>Arm 3: OL Paroxetine + DB Quetiapine</title>
            <description>In Phase II, participants will continue taking open label paroxetine and will be randomized to the addition of quetiapine (up to 800 mg daily) for 8 weeks in a double blind fashion.
Open Label (OL) Paroxetine: Open-label Paroxetine
Quetiapine: Double-blind quetiapine taken with OL paroxetine</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Clinician-Administered PTSD Scale for DSM-IV Total Score.</title>
          <description>The Clinician-Administered PTSD Scale for DSM-IV (CAPS) is described in the National Center for PTSD Instruction Manual (November 2000) as a semi-structured clinical interview designed to assess the seventeen symptoms for Post Traumatic Stress Disorder (PTSD) outlined in the DSM-IV, along with five associated features. Ratings are made on a 5 point continuum from the lowest frequency or intensity to the highest. Total CAPS score is a summed score that ranges from 0 to 136 where 0 is asymptomatic and higher scores equal more severe PTSD symptomatology. Also, a change in total CAPS score of 15 points was proposed as clinically significant change.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CAPS Total Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.15" spread="15.96"/>
                    <measurement group_id="O2" value="68.78" spread="17.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CAPS Total Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.90" spread="14.90"/>
                    <measurement group_id="O2" value="51.52" spread="19.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PANSS,HAMD,CGI,DTS, PSQI,PSQI-A, Dream/Sleep Diary,Q-LES-Q,SDS,ASEX,AIMS, BAS, SAS</title>
        <time_frame>Baseline to endpoint change scores</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Collected over 4 months per subject.</time_frame>
      <desc>Collected by open-ended questions, vitals, standardized report form, and chart review at visits every two weeks, as well as by lab assessments between phases I and II.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm 1: Open Label (OL) Paroxetine</title>
          <description>In Phase I, eligible participants will take open-label (OL) Paroxetine (up to 60 mg) daily for 8 weeks. Participants who are refractory (less than 30% reduction in CAPS scores or a minimum CAPS of 50 at week 8) and have PTSD symptoms of at least moderate severity on CGI-S will be eligible for Phase II.
Open Label (OL) Paroxetine: Open-label Paroxetine</description>
        </group>
        <group group_id="E2">
          <title>Arm 2 OL Paroxetine + DB Placebo</title>
          <description>In Phase II, participants will continue taking open label paroxetine and will be randomized to the addition of placebo for 8 weeks in a double-blind (DB) fashion.
Open Label (OL) Paroxetine: Open-label Paroxetine
Placebo: Double-blind placebo taken with OL paroxetine</description>
        </group>
        <group group_id="E3">
          <title>Arm 3: OL Paroxetine + DB Quetiapine</title>
          <description>In Phase II, participants will continue taking open label paroxetine and will be randomized to the addition of quetiapine (up to 800 mg daily) for 8 weeks in a double blind fashion.
Open Label (OL) Paroxetine: Open-label Paroxetine
Quetiapine: Double-blind quetiapine taken with OL paroxetine</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Hypotension</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="124"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hospitalized - scheduled cardiac stint</sub_title>
                <description>Scheduled cardiac stint</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="124"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalized - Suicide Ideation</sub_title>
                <description>suicide Ideation and substance abuse</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart palpitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="124"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="124"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Sexual Side effects</sub_title>
                <description>sexual dysfunction</description>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="124"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mark Hamner, MD</name_or_title>
      <organization>Ralph H. Johnson VA Medical Center</organization>
      <phone>843-789-7799</phone>
      <email>Mark.Hamner@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

